Noema Pharma AG

Noema Pharma Secures CHF 130 Million in Series B Extension Led by EQT Life Sciences

5 months ago

• Noema Pharma closed a Series B extension, raising total funding to CHF 130 million to advance its CNS disorder therapies. • The financing will support four active Phase 2 trials, with key data readouts expected in 2025 for multiple neurological assets. • Lead candidate basimglurant (NOE-101), a mGluR5 inhibitor, is being developed for trigeminal neuralgia and tuberous sclerosis complex. • EQT Life Sciences' investment underscores confidence in Noema's approach to treating underserved neurological conditions with high unmet needs.

Noema Pharma Doses First Patients in Phase 2b Gemlapodect Trial for Tourette Syndrome

7 months ago

• Noema Pharma has initiated a Phase 2b clinical trial to assess the safety and efficacy of gemlapodect (NOE-105) in treating Tourette Syndrome. • The randomized, double-blind, placebo-controlled study will enroll 140 patients across multiple centers in the US and Europe over a 12-week period. • Gemlapodect, a first-in-class phosphodiesterase-10A (PDE10A) inhibitor, aims to modulate dopamine signaling in the brain to reduce motor and vocal tics. • The primary endpoint of the trial is the Yale Global Tic Severity Scale (YGTSS) Total Tic Score, with results expected to inform future treatment strategies.